Due to typographical error in covering page resubmitting financial statements for quarter ended 30th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma's board approved unaudited standalone results for Q1 FY26 (quarter ended June 30, 2025) on August 14, 2025. Revenue from operations fell sharply to about Rs. 1.94 crore from Rs. 4.83 crore in Q1 FY25, a roughly 60% year-on-year decline. The company posted a net loss of Rs. 76.45 lakh (EPS of Rs. -2.04), narrower than the Rs. 1.49 crore loss a year ago. Total expenses stayed elevated at Rs. 2.71 crore, with raw material costs, employee costs and finance charges of Rs. 28 lakh all weighing on margins. The board also appointed Mr. Samsad Alam Khan as Secretarial Auditor for a five-year term from FY26 to FY30, subject to shareholder approval. The filing is a resubmitted version to fix a typographical error on the covering page. Notably, the prior year results included an exceptional item of Rs. 1.07 crore.
The steep revenue slump and continued losses point to ongoing operating pressure, though the smaller loss versus last year offers mild comfort. The auditor's limited review included an emphasis of matter on non-usage of certain assets, which shareholders should track for any implication on asset value or the company's going-concern position.